Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.
    Difference
    0.0%
    Check dated 2024-10-03T06:35:21.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.
    Difference
    0.4%
    Check dated 2024-09-25T23:37:56.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    ClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.
    Difference
    0.4%
    Check dated 2024-09-18T17:31:37.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The website has been updated from version v2.10.2 to v2.10.3.
    Difference
    0.0%
    Check dated 2024-09-04T06:40:48.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.0%
    Check dated 2024-08-14T01:16:37.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The results of the Phase 3 study comparing mirvetuximab soravtansine to investigator's choice chemotherapy for platinum-resistant high-grade epithelial ovarian cancer have been posted, detailing participant eligibility, treatment protocols, and outcome measures.
    Difference
    32%
    Check dated 2024-08-07T00:22:32.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.